The screening of primary open-angle glaucoma - systematic review

Boivin J F, McGregor M
Record ID 31996008425
English, French
Authors' objectives:

To assess the cost-effectiveness of a possible formal screening program for open-angle glaucoma in the province of Quebec.

Authors' results and conclusions: The scenarios based on screening that targets the population from 40 to 79 years of age, every three years, with a participation rate of 75%, therapeutic compliance of 75% and a treatment efficacy of 50%, lead to cost-effectiveness ratios of around $100,000 per year of blindness prevented. All of these calculations have been made without discounting. This type of program is a very costly option, compared to other potential health benefits that can be derived from the same resources. Reaching a better level of efficiency would require restricting screening to the 65 to 79 age bracket; even in these cases, the cost-effectiveness ration would be from $37,000 to $42,000 per year of blindness prevented for a program presenting the same characteristics in terms of frequency, participation, compliance and effectiveness. Even these costs are high compared to the health benefits.
Authors' recomendations: The analysis do not support the setting up of a formal glaucoma screening program in Quebec, both because of the high degree of uncertainty and because of the high cost such a programwould entail. However, there already exists a significant level of diagnostic activity leading to the early detection of high intraocular pressure or glaucoma. These should be maintained and restricted, the way they currently are, to the 65 to 79 age bracket. The screening tests should not be undertaken more than every three years.
Authors' methods: Review
Project Status: Completed
Year Published: 1995
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Costs and Cost Analysis
  • Epidemiology
  • Glaucoma, Open-Angle
  • Intraocular Pressure
  • Mass Screening
  • Vision Screening
Organisation Name: Conseil d'Evaluation des Technologies de la Santé du Québec
Contact Address: Conseil d'Evaluation des Technologies de la Santé du Québec, 2021, avenue Union, #1040, Montréal, Québec H3A S29, Canada. Tel: 514-873-2563; FAX: 514-873-1369
Contact Name:
Contact Email:
Copyright: Conseil d'Evaluation des Technologies de la Sante du Quebec (CETS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.